| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/12/2006 | CA2571030A1 Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| 01/12/2006 | CA2570566A1 Production of tissue factor in plants |
| 01/12/2006 | CA2570048A1 Combination therapies employing platelet aggregation drugs |
| 01/11/2006 | EP1614695A1 Polypeptide |
| 01/11/2006 | EP1614691A1 Antibacterial peptide |
| 01/11/2006 | EP1614436A1 Cellular preparation |
| 01/11/2006 | EP1614425A2 Leukotriene receptor antagonist |
| 01/11/2006 | EP1614424A1 Process for producing albumin preparation |
| 01/11/2006 | EP1614423A2 Attenuated pestiviruses |
| 01/11/2006 | EP1614418A1 use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of hyperuricaemia |
| 01/11/2006 | EP1614416A2 Method for treating amyloidosis |
| 01/11/2006 | EP1613958A2 A method for modulating nod1 activity, use of a mtp related molecule for modulating nod1 activity, and therapeutic applications thereof |
| 01/11/2006 | EP1613742A2 Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| 01/11/2006 | EP1613741A1 Perivascular mesenchymal precursor cells |
| 01/11/2006 | EP1613728A2 Modulation of diacylglycerol acyltransferase 1 expression |
| 01/11/2006 | EP1613722A2 Rna-based inhibitory oligonucleotides |
| 01/11/2006 | EP1613653A1 Secreted polypeptide species associated with cardiovascular disorders |
| 01/11/2006 | EP1613652A2 A novel method of modulating bone-related activity |
| 01/11/2006 | EP1613650A2 Severe acute respiratory syndrome (sars) causing coronavirus |
| 01/11/2006 | EP1613647A2 Use of hcv proteins |
| 01/11/2006 | EP1613620A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 01/11/2006 | EP1613397A2 Use of bacteriocin for the amelioration of digestive functionality |
| 01/11/2006 | EP1613369A2 Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives |
| 01/11/2006 | EP1613368A2 Carboxamide spirohydantoin cgrp receptor antagonists |
| 01/11/2006 | EP1613355A1 Uptake of macromolecules |
| 01/11/2006 | EP1613353A1 Pharmaceutical compositions for hepatitis c viral protease inhibitors |
| 01/11/2006 | EP1613348A2 Methods for modulating angiogenesis with apelin compositions |
| 01/11/2006 | EP1613344A2 Anti-tumor vasculature effects of human serum albumin derivatives |
| 01/11/2006 | EP1613343A2 Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| 01/11/2006 | EP1613342A1 Interferon beta in severe acute respiratory syndrome (sars) |
| 01/11/2006 | EP1613341A2 Use of slurp-1 for treating diseases related to acetylcholine receptors dysfunction |
| 01/11/2006 | EP1613340A2 Treatment of aspergillus infections with thymosin alpha 1 |
| 01/11/2006 | EP1613339A2 Anti-fungal peptidomimetics |
| 01/11/2006 | EP1613338A2 Tamandarin analogs and fragments thereof and methods of making and using |
| 01/11/2006 | EP1613337A1 Acute respiratory syndromes |
| 01/11/2006 | EP1613336A1 Histamine binding compounds for treatment method for disease conditions mediated by neutrophils |
| 01/11/2006 | EP1613335A1 Perivascular mesenchymal precursor cell induced blood vessel formation |
| 01/11/2006 | EP1613334A2 Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| 01/11/2006 | EP1613302A2 Preserved and stable compositions containing peptide copper complexes and methods related thereto |
| 01/11/2006 | EP1613294A2 Peptides and derivatives thereof as inhibitors of oxidative-induced degradation phenomena and compositions containing them |
| 01/11/2006 | EP1613274A2 Conjugates comprising human il-18 and substitution mutants thereof |
| 01/11/2006 | EP1613271A2 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 01/11/2006 | EP1613268A2 Methods for inhibition of angiogenesis |
| 01/11/2006 | EP1613267A2 Use of fgf- 18 protein, target proteins and their respective encoding nucleotide sequences to induce cartilage formation |
| 01/11/2006 | EP1613264A2 Gaucher disease drugs and methods of identifying same |
| 01/11/2006 | EP1613262A2 In vitro assays for inhibitors of hiv capsid conformational changes and for hiv capsid formation |
| 01/11/2006 | EP1613261A2 Intracellular formation of peptide conjugates |
| 01/11/2006 | EP1613210A1 LIVIN-SPECIFIC siRNAS FOR THE TREATMENT OF THERAPY-RESISTANT TUMORS |
| 01/11/2006 | EP1613168A1 Composition with heart rate reducing properties |
| 01/11/2006 | EP1556084A4 Methods of regulating body weight |
| 01/11/2006 | EP1497283A4 Maleic acid salt of(2s)-n-(5(amino(imino)methyl)-2-thienyl)methyl-1-(2r)-2-((2r)-2-((carboxymethyl)amino)3,3-diphenylpropanoyl)-2-pyrrolidine carboxamide and a process for |
| 01/11/2006 | EP1491206A4 Induction method for cell differentiation |
| 01/11/2006 | EP1485120B1 Use of one or more natural or modified oxygen carriers, devoid of plasma and cellular membrane constituents, for externally treating open, in particular chronic wounds |
| 01/11/2006 | EP1469887A4 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/11/2006 | EP1435986A4 Igf-binding protein-derived peptide or small molecule |
| 01/11/2006 | EP1414481B1 Use of cetrorelix for the treatment of jacob-creutzfeldt-disease |
| 01/11/2006 | EP1392830B1 Interleukin-18 mutants, their production and use |
| 01/11/2006 | EP1385489B1 Coated granules based on angiotensin-converting enzyme inhibitor |
| 01/11/2006 | EP1294924B1 Competitive assay for identifying allosteric inhibitors |
| 01/11/2006 | EP1252186B1 Use of neuregulin-beta as an indicator and/or target |
| 01/11/2006 | EP1165610B1 Peptide useful in treating multiple sclerosis and a pharmaceutical composition comprising the same |
| 01/11/2006 | EP1156817A4 Controlling protein levels in eucaryotic organisms |
| 01/11/2006 | EP1127064B1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| 01/11/2006 | EP1063294B1 Dnas or genes participating in parkinson's disease |
| 01/11/2006 | EP1047422B1 Use of histamine for elevating blood histamine levels |
| 01/11/2006 | EP1009768B1 Human persephin |
| 01/11/2006 | EP0868519B1 Diagnosis and treatment of aur-1 and/or aur-2 related disorders |
| 01/11/2006 | EP0830450B1 Immortalised cell lines from human adipose tissue, process for preparing same and applications thereof |
| 01/11/2006 | EP0827412B1 A method for radiolabeling a somatostatin-derived peptide analogue having one disulfide bond with a radioisotope of rhenium, and their therapeutical applications |
| 01/11/2006 | EP0823913B1 Synthesis of the breast tumor-associated antigen defined by monoclonal antibody mbr1 and uses thereof |
| 01/11/2006 | EP0787142B1 Neurturin and related growth factors |
| 01/11/2006 | EP0782616B1 Therapeutic grade thrombin production and products |
| 01/11/2006 | EP0776972B1 GENE CODING FOR IgG-Fc-BINDING PROTEIN |
| 01/11/2006 | EP0766569B1 Aav capsid vehicles for molecular transfer |
| 01/11/2006 | EP0741746B1 Analogs of thymosin alpha 1 |
| 01/11/2006 | EP0731636B1 Cdn apoptosis-modulating proteins, dna encoding the proteins and methods of use thereof |
| 01/11/2006 | EP0728209B1 Endothelin-converting enzyme |
| 01/11/2006 | CN1720336A Use of A33 antigens and JAM-IT |
| 01/11/2006 | CN1720327A Compositions, organisms and methodologies employing a novel human kinase |
| 01/11/2006 | CN1720326A Method of strengthening foreign epitope presentation by MHC class I by inhibiting TAP activity |
| 01/11/2006 | CN1720263A Trimeric binding proteins for trimeric cytokines |
| 01/11/2006 | CN1720262A Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability |
| 01/11/2006 | CN1720259A Tumor targeting agents and uses thereof |
| 01/11/2006 | CN1720258A Tumor targeting agents and uses thereof |
| 01/11/2006 | CN1720226A Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases |
| 01/11/2006 | CN1720063A Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents |
| 01/11/2006 | CN1720062A Therapeutic uses of beta-casein A<2> and dietary supplement containing beta-casein A<2> |
| 01/11/2006 | CN1720061A Compounds that bind P2Y2 or P2Y1 receptors |
| 01/11/2006 | CN1720060A Human papillomavirus polypeptides and immunogenic compositions |
| 01/11/2006 | CN1720059A Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 01/11/2006 | CN1720057A Chinese patent medicine for treating baldness and preparing process thereof |
| 01/11/2006 | CN1720034A Methods of inducing terminal differentiation |
| 01/11/2006 | CN1719984A Sustained improver of muscular fatigue |
| 01/11/2006 | CN1718735A Production of polyglutamic acid using na bean bacillus solid fermentation and its product application |
| 01/11/2006 | CN1718729A Function and use of human immune cell inhibition acceptor KLRL1 |
| 01/11/2006 | CN1718241A Buckwheat trypsase inhibitor, expression and application thereof |
| 01/11/2006 | CN1718240A Use of recombinant human interferon omega for treating anaphylactic rhinitis |
| 01/11/2006 | CN1718239A Oral adhering piece for treating oral exulceratio, and its prepn. method |
| 01/11/2006 | CN1718238A Application of nerve growth factor prepd. in medicine for treating tardive neuropathy due to toxication by organophosphorus pesticide |
| 01/11/2006 | CN1235911C Multiple cytokine-antibody complexes |